TGFB1 and type 2 diabetes mellitus: A previous study has revealed that the SGLT2 inhibitor empagliflozin ameliorates myocardial fibrosis by inhibiting the formation and deposition of collagen via the TGF-β1/Smad pathway in the mouse model of type 2 diabetes mellitus (T2DM) (Li et al., 2019).